| IPO Company Profile © ipodata.com |
| Message Board | SEC Filings | Peer IPO Companies |
| Bionumerik Pharmaceuticals, Inc. |
| 8122 Datapoint Drive, Suite 1250, San Diego, CA 78229 * (210) 614-1701 |
| Business Description | We design and develop small molecule drugs for the treatment of cancer and prevention of side effects associated with existing cancer therapies using a proprietary approach we call "mechanism-based" drug discovery. |
|
Filing Information IPO has been | |||
| To Trade As | BNPI (NASNTL) | Industry | Service (SIC 8731) |
| Type of Stock Offered | Common Shares | Filing Date | 3/2/2001 |
| Domestic Shares Filed | 0 | Filing Price | - - |
| Foreign Shares Filed | 0 | Offering Amount | $50,000,000 |
| Company Shares | 0 | Est. Expenses | - - |
| Selling Shrhldrs Shares | 0 | Post-IPO Shares | - - |
| Primary Underwriting Group | ||
| Underwriter Name | Participation | Underwriter Phone |
| Morgan Stanley Dean Witter | Lead Manager | (212) 761-5900 |
| SG Cowen | Co-manager | (212) 495-6000 |
| UBS Warburg LLC | Co-manager |
| Income Statement and Cash Flow Summary | |||||||
| Prior Audited Income |
Latest Unaudited Income | ||||||
| Full Year Audited Figures | 9 Months Ending | ||||||
| Figures in U.S. millions except per share data | 12/31/1998 | 12/31/1999 | 12/31/2000 | 12/31/1999 | 12/31/2000 | ||
| Revenues | - | - | 29.490 | 114.666 | 304.895 | 0.178 | 0.299 |
| Income from Oper. | - | - | -4.968 | -5.628 | -6.963 | -4.919 | -9.722 |
| Net Income | - | - | -4.749 | -4.986 | -6.396 | -4.531 | -8.846 |
| E.P.S | - | - | -1.370 | -1.430 | -1.810 | -1.280 | -2.440 |
| Revenue Growth (%) | - | - | 288.83 | 165.898 | 68.08 | ||
| Net Income Growth (%) | - | - | - | - | - | ||
| Oper. Profit Margin (%) | - | - | - | - | - | - | - |
| Net Profit Margin (%) | - | - | - | - | - | - | - |
| Cash Flow - Oper. | -3.20 | -1.96 | -4.96 | ||||
| Cash Flow - Inv. | -0.21 | -1.26 | -2.00 | ||||
| Cash Flow - Fin. | 11.22 | 1.08 | 4.87 | ||||
| Balance Sheet Summary and Financial Ratios | |||||
| Balance sheet as of: 12/31/2000 | Financial Ratios | ||||
| Total Assets | 20.88 | Current Assets | 18.30 | Current Ratio | 11.11 |
| Total Liab. | 6.63 | Current Liab. | 1.65 | Debt Ratio | 31.77% |
| Total Equity | 14.25 | Working Cap. | 16.65 | Debt to Equity Ratio | 0.47 |
| Cash | 18.04 | Return on Assets | - | ||
| Use Of Proceeds |
The proceeds from the proposed offering will be used for research and development activities, including clinical trials and for working capital and general corporate purposes. |
| Legal Counsel Registrar Auditor | |
| Issuer's Law Firm | Wilson, Sonsini, Goodrich & Rosati |
| Bank's Law Firm | Ropes & Gray |
| Registrar/Transfer Agent | ChaseMellon Shareholder Services, L.L.C. |
| Auditor | Ernst & Young |
| Send us feedback if you would like to request that we hyperlink a firm on this page | |
| Principal Shareholders | ||
| Name of Shareholder | % Owned Before | % Owned After |
| Bioven Partners, L.P. | 7.20 | |
| Note: represents ownership of 5% or more prior to the offering. | ||